2,6-di-imidazol-1-yl-cyclohexanol | 1119458-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,6-di-imidazol-1-yl-cyclohexanol
• 英文别名: 2,6-Di(imidazol-1-yl)cyclohexan-1-ol
• CAS: 1119458-72-8
• 化学式: C₁₂H₁₆N₄O
• 分子量: 232.285
• InChiKey: UDTNQEWNDNYUKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氟三氟甲苯 、 2,6-di-imidazol-1-yl-cyclohexanol 在 potassium tert-butylate 作用下， 以 二甲基亚砜 为溶剂， 以94%的产率得到2,6-bis-imidazol-1-yl-1-(4-trifluoromethylphenoxy)-cyclohexane
  参考文献：
  名称：

  Aryloxy cyclohexyl imidazoles: A novel class of antileishmanial agents

  摘要：

  Thirteen novel aryloxy cyclohexane-based mono and bis imidazoles were synthesized and evaluated in vitro as antileishmanials against Leishmania donovani and cytotoxicity assessed. These compounds were better than the existing drugs, sodium stibogluconate and pentamidine in respect to IC50 and SI values. Promising compounds were tested further in vivo. Among all, the bis methylimidazole with 2-fluoro, 4-nitro aryloxy group (9) exhibited significant in vivo inhibition of 77.9%, thus providing new structural lead for antileishmanials. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.094
• 作为产物：
  描述：

  2,6-diimidazol-1-yl-cyclohexanone 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 2.5h， 以87%的产率得到2,6-di-imidazol-1-yl-cyclohexanol
  参考文献：
  名称：

  Aryloxy cyclohexyl imidazoles: A novel class of antileishmanial agents

  摘要：

  Thirteen novel aryloxy cyclohexane-based mono and bis imidazoles were synthesized and evaluated in vitro as antileishmanials against Leishmania donovani and cytotoxicity assessed. These compounds were better than the existing drugs, sodium stibogluconate and pentamidine in respect to IC50 and SI values. Promising compounds were tested further in vivo. Among all, the bis methylimidazole with 2-fluoro, 4-nitro aryloxy group (9) exhibited significant in vivo inhibition of 77.9%, thus providing new structural lead for antileishmanials. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.094